ADD blurb about a carcinogen (that is, GraphPad)

tex/thesis.tex

@@ -3931,7 +3931,6 @@ responsible for this, and further that the unique \textit{cis/trans} activity of
 \gls{il15} may be more active in the \gls{dms} system due to higher cell
 density.
 
-% FIGURE this should say ug not mg
 \begin{figure*}[ht!]
   \begingroup
 
@@ -3967,7 +3966,6 @@ samples, simply lining up their histograms showed no difference between any of
 the markers, and by extension showing no difference in phenotype
 (\cref{fig:il15_1_mem}).
 
-% FIGURE this should say ug not mg
 \begin{figure*}[ht!]
   \begingroup
 
@@ -4193,7 +4191,6 @@ between survival groups.
 \subsection{DMS-expanded T Cells Show Greater Anti-Tumor Activity \invivo{}
   Compared to Beads}
 
-% FIGURE put growth first in this figure
 \begin{figure*}[ht!]
   \begingroup
 
@@ -4214,7 +4211,6 @@ between survival groups.
   \label{fig:mouse_dosing_qc}
 \end{figure*}
 
-% FIGURE explain what statistical test was used here
 \begin{figure*}[ht!]
   \begingroup
 
@@ -4238,7 +4234,9 @@ between survival groups.
       only those that received a comparable number of \gls{car} T cells.}
     \subcap{fig:mouse_dosing_ivis_survival_full}{The same data as
       \subref{fig:mouse_dosing_ivis_survival} except showing the full time until
-    euthanasia for all mice (including those that died via \gls{gvhd}).}
+    euthanasia for all mice (including those that died via \gls{gvhd}). Survival
+    curves were statistically analyzed using the logrank test in GraphPad
+    Prism.}
   }
   \label{fig:mouse_dosing_ivis}
 \end{figure*}